Updated · Investors | Eli Lilly and Company · Jun 6
Lilly Says Retatrutide Cut Weight 28.3% and A1C 2.0% in Phase 3 Trials
Updated
Updated · Investors | Eli Lilly and Company · Jun 6
Lilly Says Retatrutide Cut Weight 28.3% and A1C 2.0% in Phase 3 Trials
3 articles · Updated · Investors | Eli Lilly and Company · Jun 6
Summary
Retatrutide 12 mg helped obesity patients lose an average 70.3 pounds, or 28.3%, over 80 weeks in Lilly’s Phase 3 TRIUMPH-1 trial, with 65.3% falling below the BMI threshold for obesity.
The same study also met primary endpoints for obesity-related complications, reducing knee osteoarthritis pain by up to 4.3 points, or 73.1%, and moderate-to-severe sleep apnea by up to 36.1 events an hour, or 60.6%.
In the separate Phase 3 TRANSCEND-T2D-1 trial, retatrutide cut A1C by up to 2.0% at 40 weeks in adults with type 2 diabetes, while 90% reached below 7.0% and up to 46% reached normal A1C levels.
Weight loss in diabetes patients reached 36.6 pounds, or 16.8%, at 12 mg and had not plateaued at 40 weeks; Lilly also reported improvements in triglycerides, non-HDL cholesterol, blood pressure and waist circumference across both trials.
Gastrointestinal side effects such as nausea, diarrhea and vomiting were the most common, with discontinuation rates rising to 11.3% at the highest dose in TRIUMPH-1; the once-weekly triple agonist remains investigational.
Retatrutide alters three core metabolic hormones. What are the unknown long-term health risks of this powerful intervention?
Genetic markers can predict drug efficacy. Is personalized obesity medicine finally on the horizon for patients?
Lilly's new drug has a $1,500 monthly price tag. Will this 'miracle' cure deepen healthcare inequality?
Retatrutide’s Phase 3 Triumph: Up to 24% Weight Loss and Broad Metabolic Benefits Signal Paradigm Shift in Obesity and Diabetes Care
Overview
Eli Lilly’s TRIUMPH program is a major research effort evaluating retatrutide, a new treatment for metabolic diseases. The program includes several ongoing Phase III trials, with early results from the TRIUMPH-4 trial already showing promise. TRIUMPH aims to prove retatrutide’s safety and effectiveness for conditions like obesity, overweight with other health problems, and Type 2 diabetes. It also explores the drug’s potential for treating obstructive sleep apnea and knee osteoarthritis. With seven more Phase III trial results expected by 2026, the program is set to deliver important new insights into retatrutide’s benefits across multiple conditions.